-
2023-505334-10-01
7
2024-10-30
Unresectable, Locally Advanced, or Metastatic Solid Tumors
-
2023-509560-16-00
5
2024-10-29
Juvenile psoriatic arthritis (jPsA)
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2023-509851-15-00
5
2024-10-22
Colon cancer
-
2023-509706-30-00
5
2024-10-18
Heart failure (HF)
-
2023-504724-25-00
5
2024-10-16
Primary Myelofibrosis
-
2024-516782-36-00
4
2024-10-15
metastatic or recurrent endometrial or ovarian carcinosarcoma
-
2023-506686-66-01
10
2024-10-09
HLA-A2 negative metastatic uveal melanoma
-
2023-508581-15-00
5
2024-10-08
Heart condition
-
2024-514304-14-00
1
2024-10-08
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
-
2023-507482-26-00
5
2024-10-04
Castrate-resistant prostate cancer with oligometastases on functional
-
2023-508338-33-00
5
2024-10-01
Chronic Inflammatory Demyelinating Polyneuropathy
-
2024-513971-42-00
5
2024-10-01
Chronic heart failure (NYHA I-III) and non-dialysis CKD
-
2024-512921-10-00
1
2024-09-27
Advanced and/or Metastatic Solid Tumors
-
2023-507064-39-00
5
2024-09-26
generalized Myasthenia Gravis
-
2023-507803-76-00
10
2024-09-26
Peripheral T-Cell Lymphoma
-
2023-508811-21-00
10
2024-09-25
Refractory Focal Onset Epilepsy
-
2024-511238-11-00
1
2024-09-20
Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lu
-
2022-500800-24-00
4
2024-09-19
Multiple Myeloma
-
2023-508258-24-00
4
2024-09-12
Ovarian cancer (OC) with oligometastatic progression (OMP).
-
2023-507353-15-00
5
2024-09-10
idiopathic pulmonary fibrosis (IPF)
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2023-506159-12-00
10
2024-09-06
Generalized Myasthenia Gravis
-
2023-505616-38-00
4
2024-09-04
Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (